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ABSTRACT
Purpose: To investigate the factors associated with hepatobiliary phase (HBP) 
enhancement at gadoxetic acid-enhanced magnetic resonance imaging (MRI) and to 
determine whether HBP images could be used to predict prognosis in patients with 
colorectal cancer liver metastasis (CRLM).
Results: Of the 96 total nodules, 65 and 31 nodules were in the mixed and 
clearly hypointense groups, respectively. In the 55 nodules without preoperative 
chemotherapy, organic anionic transporting polypeptide 1B3 (OATP1B3) expression 
was a significant factor regarding the HBP enhancement (P=0.042). In this subgroup, 
nodules with OATP1B3 expression displayed a significantly higher relative intensity 
ratio on the HBP image (RIRpost) and relative enhancement ratio (RER) than those 
lacking this marker (P=0.024, 0.003, respectively). No significant factor was 
associated with the enhancement pattern in the chemotherapy group. The mixed 
hypointense group displayed worse survival rates (P=0.002).
Materials and Methods: Ninety-six patients who underwent pre-operative 
liver MRI and surgical resection for CRLM from January 2010 to June 2012 were 
retrospectively analyzed. We qualitatively evaluated the HBP enhancement pattern of 
CRLMs and classified them into mixed and clearly hypointense groups. For quantitative 
measurement, the RIRpost and RER were analyzed. To investigate factors associated 
with HBP enhancement, tumor components (fibrosis, necrosis, and cellularity) and 
OATP1B3 expression were scored on a 4-point scale. Univariate and multivariate 
analyses were done to determine significant factors for visual enhancement and 
quantitative parameters.
Conclusions: OATP1B3 expression is associated with mixed hypointense CRLMs 
without chemotherapy. Signal intensity on HBP has potential usefulness to predict 
prognosis in CRLMs.
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INTRODUCTION
Colorectal cancer (CRC) is the third-most common 
cancer worldwide [1, 2]. Hepatic metastases from CRC 
are an important clinical problem because the liver is the 
most frequent site of metastasis, and their presence can 
significantly change the treatment plan and outcome [3]. 
Gadoxetic acid-enhanced MRI is an established method 
widely used for the evaluation of colorectal cancer liver 
metastasis (CRLM) because the hepatobiliary phase 
(HBP) offers excellent lesion to liver contrast, leading to a 
higher lesion detection rate [4].
Gadoxetic acid is a liver-specific MRI contrast 
agent whose uptake is mediated by the organic anionic 
transporting polypeptide 1B3 (OATP1B3) expressed 
by hepatocytes. The general belief has been that tumors 
of non-hepatocyte origin, including CRLMs, could not 
actively uptake gadoxetic acid and, therefore, lacked 
a T1 contrast effect on the HBP [5]. However, a recent 
study reported that 72% of CRLMs show mixed signal 
intensity (SI) on HBP, vaguely assumed to be the result 
of gadoxetic acid retention within the extracellular space 
where abundant desmoplasia and intraacinar necrosis 
exist [6], but the underlying mechanism remains poorly 
understood.
Accumulating evidence indicates that OATP1B3 is, 
in fact, not exclusively expressed by hepatocytes; aberrant 
OATP expression occurs in various human malignancies 
arising from the colon, pancreas, gall bladder, lung, and 
breast in addition to hepatocellular carcinomas [7–14]. 
Moreover, experimental evidence has indicated that 
aberrant expression of OATP1B3 is associated with 
decreased apoptosis following chemotherapy and more 
aggressive tumor behavior, implicating the expression of 
this marker as a potentially adverse prognostic factor [13]. 
However, to our knowledge no study has been performed 
to elucidate whether or not such aberrant expression of 
OATP1B3 has an influence on the imaging features of a 
gadoxetic acid-enhanced MRI.
We hypothesized that if OATP1B3 is responsible for 
the intracellular transport of gadoxetic acid, theoretically 
the aberrant expression of OATP1B3 may influence 
the MRI enhancement pattern even in tumors of non-
hepatocyte origin.
The purpose of this study was to elucidate the 
factors that might influence the enhancement pattern of 
a CRLM on a gadoxetic acid-enhanced MRI and, if so, 
whether they were associated with the clinical outcome.
RESULTS
Enhancement pattern of the metastatic liver 
nodules
Among the 96 nodules (Supplementary Figure 1), 
65 nodules (68%) and 31 nodules (32%) were classified 
as mixed hypointense nodules and clearly hypointense 
nodules, respectively (Figures 1–2). Among the patients 
who did not receive preoperative chemotherapy (non-
chemotherapy group: n=55), 34 nodules (62%) showed a 
mixed hypointense signal intensity (SI), and 21 nodules 
(38%) showed a clearly hypointense SI in the HBP. In the 
chemotherapy group (n=41), 31 nodules (76%) showed a 
mixed hypointense SI, and 10 nodules (24%) showed a 
clearly hypointense SI. There was no significant difference 
in the enhancement pattern between the non-chemotherapy 
and chemotherapy groups (P=0.1529).
Histopathologic parameters and OATP1B3 
immunohistochemistry
The histopathological parameters were analyzed as 
fibrosis grade (G1, 59 [61%]; G2, 25 [26%]; G3, 9 [9%]; 
and G4, 3 [3%]), necrosis grade (G1, 32 [33%]; G2, 23 
[24%]; G3, 19 [20%]; and G4, 22 [23%]), and cellularity 
grade (G1, 36 [38%]; G2, 19 [20%]; G3, 28 [29%]; and 
G4, 13 [14%]), respectively. The results of each parameter 
within the chemotherapy group and the non-chemotherapy 
group were also provided (Table 1).
OATP1B3 immunohistochemistry revealed 30 
nodules showing weakly positive expression and 6 nodules 
with moderately positive expression of OATP1B3. In 
concordance with a previous report [13], we observed that 
unlike normal liver tissue (positive control, Supplementary 
Figure 2) that displayed a membranous OATP1B3 
expression, all of these OATP1B3-positive CRLM nodules 
(n=36) showed cytoplasmic OATP1B3 expression. The 
other 60 nodules lacked OATP1B3 activity.
Correlation of the qualitative imaging analysis 
with the histopathology
We separately performed univariate and multivariate 
analyses for the chemotherapy and non-chemotherapy 
groups. In the non-chemotherapy group (n=55), no 
factor seemed to be significantly associated with the 
enhancement pattern of CRLMs in univariate analysis. 
However, the multivariate analysis identified positive 
OATP1B3 expression (P=0.042) and fibrosis grade 
(P=0.029) as factors significantly associated with the 
HBP enhancement pattern (Table 1). In specific, 19 of the 
35 OATP1B3-negative CRLM nodules (54%) displayed 
a mixed hypointense pattern during the HBP; whereas, 
15 of the 20 OATP1B3-positive CRLM cases (75%) 
were mixed hypointense nodules (Figure 3). In the non-
chemotherapy group, fibrosis was also significant factor 
showing an inverse correlation with the enhancement 
pattern (P=0.029; Table 1). In the chemotherapy group, 
we could find no significant factor associated with the 
enhancement pattern in both univariate and multivariate 
analyses.
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Figure 1: Gadoxetic acid-enhanced MRI of a CRLM diagnosed by surgical resection in a 61-year-old man.  (A) Precontrast 
T1-weighted image showed a hypointense nodule (arrow) in segment 8. (B) The tumor (arrow) showed mixed hypointensity during the 
hepatobiliary phase (HBP) of a liver dynamic MRI. (C) Hematoxylin and eosin staining revealed grade 1 fibrosis, grade 2 central necrosis, 
and grade 3 cellularity. (D) Immunohistochemistry (×100) revealed weak expression of OATP1B3 (arrowhead) in 20% of the tumor.
Figure 2: Gadoxetic acid-enhanced MRI of a CRLM diagnosed by surgical resection in a 49-year-old man.  (A) 
Precontrast T1-weighted image showed a hypointense nodule (arrow) in segment 6. (B) The tumor (arrow) showed a clear hypointensity 
during the hepatobiliary phase (HBP) of a liver MRI. (C) Hematoxylin and eosin staining revealed grade 1 fibrosis, grade 2 central necrosis, 
and grade 3 cellularity. (D) Immunohistochemistry (×100) revealed a lack of expression of OATP1B3 in the tumor but strong expression in 
the surrounding liver parenchyma (arrowhead).
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Correlation of the quantitative imaging analysis 
with the histopathology
In the non-chemotherapy group, the mean relative 
intensity ratio on the HBP image (RIRpost), relative 
intensity ratio on the precontrast image (RIRpre), 
relative enhancement ratio (RER), and contrast to noise 
ratio (CNR) values were 0.46, 0.68, 0.67, and -19.62, 
respectively. In the univariate analysis, nodules positive 
for OATP1B3 expression possessed significantly higher 
RIRpost and RER values when compared with that of the 
lesions without OATP1B3 expression (P=0.014, 0.005, 
respectively; Table 2  and Figure 4). Nodules with high-
grade cellularity (G2-4) also possessed significantly higher 
CNR values than that of the nodules with low-grade (G1) 
cellularity (P=0.029; Table 2). In the multivariate analysis, 
positive OATP1B3 expression was associated with higher 
RIRpost and RER values in comparison with lesions lacking 
OATP1B3 expression (P=0.024, 0.003, respectively; 
Table 3  and Figure 4). However, cellularity failed to 
reach statistical significance in the multivariate analysis, 
including CNR (P=0.144).
In the chemotherapy group, the mean RIRpost, 
RIRpre, RER, and CNR values were 0.51, 0.74, 0.69, and 
-16.52, respectively. None of the parameters we examined 
reached statistical significance in regard to the quantitative 
parameters (RIRpost, RIRpre, RER, and CNR values) in 
either the univariate or multivariate analyses (Tables 2–3).
Imaging features and clinical outcome
The mean follow-up interval for the 96 patients was 
1336 days (range 59–2555 days). Forty-eight patients died 
during the follow-up period. Sixty-four patients developed 
local recurrence of primary colon cancer and/or metastases 
after a curative surgical resection; local recurrence of the 
primary colon cancer at the resection site occurred in two 
patients. Metachronous distant metastases developed in the 
liver (n=12), liver and lung (n=11), liver and peritoneum/
omentum (n=6), liver and lymph node (n=2), liver and 
brain (n=1), lung (n=15), lung and peritoneum/omentum 
(n=1), lung and lymph node (n=1), lung and ovary (n=1), 
lymph node (n=8), peritoneum/omentum (n=3), and brain 
and spinal cord (n=1).
The estimated 5-year survival rate was 52.5%, and 
the mean survival time was 1623 days. The estimated 
5-year disease-free survival rate was 33.1%, and the 
mean recurrence-free time was 1004 days. The patients 
Table 1: Result of univariate and multivariate analyses of histopathologic factors accounting for the visual 
enhancement pattern
Mixed 
hypointense
Clearly 
hypointense
Univariate analysis Multivariate analysis
Exp (B) value P value Exp (B) value
95% 
confidence 
interval
P value
Non preoperative chemotherapy group
OATP1B3 
(-/+)
19/15 
(56%/44%)
16/5 
(76%/24%)
2.526 0.134 5.694
1.067–
30.379
0.042
Fibrosis (G1/
G2-4)
28/6 
(82%/18%)
13/8 
(62%/38%)
0.348 0.097 0.197 0.046–0.850 0.029
Necrosis (G1/
G2-4)
14/20 
(41%/59%)
7/14 
(33%/67%)
0.714 0.561 1.165 0.274–4.960 0.837
Cellularity 
(G1/G2-4)
11/23 
(32%/68%)
5/16 
(24%/76%)
1.530 0.499 3.301
0.737–
14.792
0.119
Preoperative chemotherapy group
OATP1B3 
(-/+)
19/12 
(61%/39%)
6/4 
(60%/40%)
1.056 0.942 1.025 0.227–4.635 0.975
Fibrosis (G1/
G2-4)
12/19 
(39%/61%)
6/4 
(60%/40%)
0.421 0.245 2.413
0.501–
11.631
0.272
Necrosis (G1/
G2-4)
9/22 
(29%/71%)
2/8 
(20%/80%)
1.636 0.577 0.754 0.116–4.911 0.768
Cellularity 
(G1/G2-4)
16/15 
(52%/48%)
4/6 
(40%/60%)
1.600 0.525 1.880 0.416–8.490 0.412
* Exp(B): Exponentiation of the B coefficient, OATP1B3: Organic anionic transporting polypeptide 1B3.
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Figure 3: A graph showing the proportion of clearly hypointense and mixed hypointense CRLMs without chemotherapy 
in relation to OATP1B3 expression.
Table 2: Results of the univariate analyses of histopatholgic factors for the quantitative parameters
RIRpost RIRpre RER CNR
Univariate analysis
RIRpost RIRpre RER CNR
B 
value
P 
value
B 
value
P 
value
B 
value
P 
value
B 
value
P 
value
Non preoperative chemotherapy group
OATP1B3 
(-/+)
0.4244/0.5109 0.6780/0.6836 0.6274/0.7467
-21.1087/-
17.0274
0.086 0.014 0.006 0.860 0.119 0.005 4.081 0.074
Fibrosis 
(G1/G2-4)
0.4632/0.4345 0.6806/0.6785 0.6820/0.6378
-19.0491/-
21.3100
-0.029 0.472 -0.002 0.954 -0.044 0.364 -2.261 0.375
Necrosis 
(G1/G2-4)
0.4927/0.4331 0.6963/0.6700 0.7012/0.6520
-19.7470/-
19.5489
-0.060 0.091 -0.026 0.399 -0.049 0.258 0.198 0.931
Cellularity 
(G1/G2-4)
0.4560/0.4558 0.6782/0.6808 0.6740/0.6695
-23.3485/-
18.0968
<0.001 0.996 0.003 0.937 -0.005 0.923 5.252 0.029
Preoperative chemotherapy group
OATP1B3 
(-/+)
0.5152/0.4902 0.7597/0.7097 0.6791/.6970
-16.2539/-
16.9190
-0.025 0.540 -0.050 0.199 0.018 0.690 -0.665 0.771
Fibrosis 
(G1/G2-4)
0.4851/0.5213 0.7381/0.7414 0.6705/0.6986
-17.2433/-
15.9417
0.036 0.364 0.003 0.931 0.028 0.524 1.302 0.562
Necrosis 
(G1/G2-4)
0.5572/0.4875 0.7499/0.7365 0.7440/0.6663
-14.7342/-
17.1296
-0.070 0.121 -0.013 0.760 -0.078 0.117 -2.395 0.347
Cellularity 
(G1/G2-4)
0.5156/0.4945 0.7604/0.7185 0.6792/0.6935
-15.7042/-
17.3682
-0.021 0.596 -0.042 0.273 0.014 0.744 -1.664 0.455
* RIRpost: Relative intensity ratio on the HBP image, RIRpre: Relative intensity ratio on the precontrast image, RER: Relative 
enhancement ratio, CNR: Contrast to noise ratio, OATP1B3: Organic anionic transporting polypeptide 1B3.
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with mixed hypointense nodule(s) showed inferior overall 
survival when compared with those of patients with clearly 
hypointense nodule(s) (P=0.002; Figure 5A). The patients 
with mixed hypointense nodule(s) showed a tendency 
of worse disease-free survival compared with those 
of patients with clearly hypointense nodule(s), but the 
difference did not reach statistical significance (P=0.068; 
Figure 5B). In regard with OATP1B3 expression, no 
significant difference was found between the OATP1B3 
positive group and negative group in both overall survival 
and disease-free survival (P=0.411, 0.541, respectively; 
Supplementary Figure 3).
DISCUSSION
Gadoxetic acid is a potent hepatocyte-specific MRI 
contrast agent that selectively and robustly enhances the 
normal liver tissue, and has a proven role to improve the 
delineation and detection of space occupying lesions [13]. 
This finding has led to a widespread stereotype among 
clinicians and radiologists that liver metastases will show 
minimal or no enhancement on gadoxetic acid-enhanced 
MRIs. However, recent publications have reported that 
tumor enhancement quite frequently occurs in CRLMs 
and breast cancer liver metastases on gadoxetic acid-
enhanced MRIs, the underlying cause of which was 
vaguely assumed to be the result of passive diffusion of 
the contrast agent into the interstitial space [6, 15]. Along 
similar lines, we observed mixed hypointensity on MRIs 
in up to 68% (n=65/96) of CRLMs. However, our data 
showed an inverse correlation with fibrosis grade in the 
non-chemotherapy group and no identifiable correlation 
in the chemotherapy group, suggesting that fibrosis may 
not be as important a factor as previously assumed. 
Figure 4:Box plots showing four MR quantitative parameters of CRLMs without chemotherapy. (A) relative intensity ratio 
on the hepatobiliary phase (HBP) image (RIRpost), (B) relative intensity ratio on the precontrast image (RIRpre), (C) relative enhancement 
ratio (RER), and (D) contrast to noise ratio (CNR).  * P value < 0.05.
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Instead, we found that the mixed hypointense CRLM was 
associated with positive OATP1B3 immunoreactivity of 
tumor cells in patients who did not receive chemotherapy.
OATP1B3 is a highly active membrane carrier 
protein that is responsible for gadoxetic acid transport 
into hepatocytes. In addition, a subpopulation of 
hepatocellular carcinomas and adenomas are also known 
to express OATP1B3, resulting in significant tumor 
enhancement on gadoxetic acid-enhanced MRIs [16, 
17]. The native OATP1B3 protein expressed in normal 
hepatocytes and these tumors of hepatocyte origin 
typically shows membranous distribution [18, 19]. 
Meanwhile, accumulating evidence has indicated that 
aberrant OATP1B3 expression occurs in a significant 
proportion of tumors of non-hepatocyte origin, such 
as colon cancer, breast cancer, pancreatic cancer, and 
prostate cancer [10–14, 18, 20]. The aberrant OATP1B3 
protein produced in these tumors seems to differ from that 
of native OATP1B3 protein in that the aberrant version 
typically contains mutations and has a cytoplasmic rather 
than membranous distribution, implying that the aberrant 
copies of OATP1B3 might be functionally defective.
To the best of our knowledge, no study has 
elucidated whether aberrant OATP1B3 proteins (which 
are potentially functionally defective) expressed in 
tumors of non-hepatocyte origin have an influence on the 
enhancement profile of a gadoxetic acid-enhanced MRI. 
Similar to previous reports that described the cytoplasmic 
distribution of aberrant OATP1B3 protein [21, 22], 
all of the CRLMs with positive OATP1B3 expression 
in our study showed cytoplasmic not membranous 
distribution of the transporter (Figure 1C). In addition, 
the aberrant expression of OATP1B3 was associated 
with mixed hypointensity of CRLMs on gadoxetic acid-
enhanced MRIs in the non-chemotherapy group, which 
we interpret to be the result of preserved (but probably 
attenuated) transport function of this carrier protein. Our 
conclusion is compatible with the experimental data 
based on a colon cancer cell line, which demonstrated that 
aberrant OATP1B3 protein was capable of transporting 
several substrates - including gadoxetic acid, despite its 
cytoplasmic distribution [22].
By contrast, we have failed to identify any 
association in the chemotherapy group between 
Table 3: Results of the multivariate analyses of histopathologic factors for the quantitative parameters
Multivariate analysis
RIRpost RIRpre RER CNR
B value 95% CI P value
B 
value
95% 
CI
P 
value
B 
value
95% 
CI
P 
value
B 
value
95% 
CI
P 
value
Non preoperative chemotherapy group
OATP1B3 
(-/+)
0.093
0.013–
0.174
0.024 -0.008 -0.084–
0.174
0.841 0.150
0.054–
0.174
0.003 3.985 -1.276–
0.174
0.134
Fibrosis (G1/
G2-4) -0.053
-0.131–
0.024
0.171 -0.005
-0.078–
0.024
0.892 -0.077
-0.169–
0.024
0.101 -2.410
-7.435–
0.024
0.340
Necrosis (G1/
G2-4) -0.028
-0.131–
0.047
0.455 -0.030
-0.101–
0.047
0.400 0.002
0.087–
0.04
0.956 1.569
-3.318–
0.047
0.522
Cellularity 
(G1/G2-4)
-0.036
-0.114–
0.041
0.352 0.005
-0.069–
0.041
0.901 -0.061
-0.154–
0.041
0.190 3.729
-1.320–
0.041
0.144
Preoperative chemotherapy group
OATP1B3 
(-/+)
-0.021
-0.103–
0.062
0.611 -0.051
-0.131–
0.029
0.201 0.022
-0.070–
0.114
0.629 -0.526
-5.234–
4.182
0.822
Fibrosis (G1/
G2-4) 0.019
-0.067–
0.104
0.658 -0.004
-0.087–
0.078
0.919 0.011
-0.084–
0.106
0.819 0.808
-4.070–
5.686
0.739
Necrosis (G1/
G2-4) -0.069
-0.166–
0.028
0.157 -0.022
-0.116–
0.072
0.639 -0.074
-0.183–
0.034
0.172 -2.519
-8.064–
3.026
0.363
Cellularity 
(G1/G2-4)
-0.034
-0.116–
0.047
0.396 -0.046
-0.125–
0.032
0.242 0.002
-0.088–
0.093
0.957 -2.157
-6.797–
2.483
0.353
* RIRpost: Relative intensity ratio on the HBP image, RIRpre: Relative intensity ratio on the precontrast image, RER: 
Relative enhancement ratio, CNR: Contrast to noise ratio, CI: confidence interval, OATP1B3: Organic anionic transporting 
polypeptide 1B 3.
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OATP1B3 expression and the enhancement pattern 
on MRI. Theoretically, chemotherapy can impair 
OATP1B3 function by causing cellular damage [23] 
and by aggravating fibrosis and necrosis. Therefore, we 
speculated that chemotherapy may consequently provoke 
passive retention of gadoxetic acid within the extracellular 
space irrespective of OATP1B3 function. Collectively, the 
mixed effect of the passive retention of a contrast agent in 
the stroma and the variable degree of OATP1B3 carrier 
function (especially after chemotherapy) probably results 
in variable signal intensity in the HBP on gadoxetic acid-
enhanced MRIs [24, 25].
Our results demonstrated that mixed hypointense 
CRLMs are associated with a worse prognosis compared 
to that of clearly hypointense lesions. Interestingly, 
several studies have reported that aberrant OATP1B3 
expression is associated with a poor prognosis. Lee et al. 
demonstrated that aberrant OATP1B3 overexpression in 
a colon cancer cell line interferes with the p53 signaling 
pathway, providing experimental evidence that OATP1B3 
overexpression is associated with reduced apoptosis and 
the survival advantage of cancer cells [13]. Similarly, 
colon cancer patients with OATP1B3 overexpression 
revealed by immunohistochemistry was reported to 
display a worse progression-free survival rate when 
compared with patients with scanty or negative OATP1B3 
expression [26]. However, in our study we could not detect 
significant influence of OATP1B3 expression on overall 
survival and disease free survival. Collectively, we believe 
that mixed hypointensity of a CRLM is a feature that can 
be applied as a potential imaging biomarker to screen for 
high-risk patients, although we do not exactly understand 
the underlying mechanism that was responsible for the 
difference in clinical outcome.
There are several limitations to this study. First, 
there might be selection bias because we only enrolled 
surgically resected CRLMs larger than 2 cm. Also, the 
lack of inclusion for patients who received chemotherapy 
in combination with non-surgical local treatments such 
as radiofrequency ablation or those who underwent non-
curative resection limits the application of our conclusion 
to certain clinical settings. Second, the retrospective 
nature of the study prevented us from standardizing the 
treatment protocol and imaging parameters and matching 
the histopathologic examination and MR imaging 
completely slice-by-slice. The variability in chemotherapy 
regimen could have had some influence on the HBP 
enhancement pattern and clinical outcome. Third, we were 
not able to provide experimental evidence regarding the 
carrier function of aberrant OATP1B3 proteins in terms 
of their capacity for gadoxetic acid transport. Fourth, 
the state of OATP1B3 expression did not show direct 
influence on clinical outcome. Therefore, we were not 
able to explain the underlying mechanism why mixed 
hypointense CRLM lesions were associated with worse 
prognosis. Fifth, aberrant OATP1B3 expression was 
observed in both chemotherapy and non-chemotherapy 
groups but was significantly associated with the mixed 
hypointensity on gadoxetic acid-enhanced MRI only in the 
non-chemotherapy group. We were not able to clarify the 
reason why OATP1B3 expression did not seem to affect 
the MRI enhancement profile in the chemotherapy group. 
To resolve the latter two limitations, we believe that a 
genetic analysis including, but not limited to, DNA and/or 
Figure 5: Kaplan-Meier survival curves in CRLM patients based on the visual enhancement pattern of the tumor 
during the hepatobiliary phase (HBP).
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mRNA sequencing of the aberrant copies of OATP1B3 is 
required, but this analysis is not feasible using formalin-
fixed, paraffin-embedded samples.
In conclusion, a considerable portion of CRLMs 
showed mixed hypointensity on gadoxetic acid-enhanced 
MRI that seems to be a phenomenon poorly linked 
with fibrosis, but instead can be accounted for by the 
aberrant tumor expression of OATP1B3 at least in the 
non-chemotherapy group. Mixed hypointense CRLMs 
had potential association with a worse prognosis, and, 
therefore, we believe that this enhancement pattern can be 
applied as a potential imaging biomarker.
MATERIALS AND METHODS
This retrospective study was approved by the 
institutional review board and a waiver for informed 
consent was obtained.
Patients
We analyzed 208 consecutive CRLM patients who 
underwent a curative surgical resection at our hospital 
from January 2010 to June 2012. We excluded patients 
with 1) a history of previous local treatment such as 
radiofrequency ablation therapy or a transcatheter 
arterial chemoembolization (TACE; n=27), 2) patients 
who lacked pre-operative gadoxetic acid–enhanced MRI 
(n=13), 3) patients who had a poor quality pre-operative 
gadoxetic acid-enhanced MRI (n=2), and 4) patients 
who had nodules in which the maximum diameter 
of the lesion was <2 cm on the MRI to minimize the 
error in the ROI measurement and visual assessment 
(n=70; Supplementary Figure 1). Therefore, our final 
study population consisted of 96 histologically proven 
CRLM patients [60 men and 36 women; median age = 
58 years (30-81 years)]. 96 CRLM patients had total of 
129 nodules (nodules per patient, 1.34; range, 1-6). We 
selected the largest nodule for analysis in 20 patients with 
multiple CRLMs because CRLMs in the same patient 
showed similar characteristics. Finally our study group 
consisted of 96 nodules in the 96 histologically proven 
CRLM patients. Among the 96 patients, 55 (57%) patients 
did not have a history of chemotherapy, and 41 patients 
(43%) had received chemotherapy at the time when the 
MRI was performed. The chemotherapy regimens used 
in the chemotherapy group (n=41) were as follows: 
FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin; 
n=24, 59%), FOLFOX+bevacizumab (n=8, 20%), 
FOLFOX+cetuximab (n=4, 10%), FOLFIRI (folinic acid, 
5-fluorouracil, and irinotecan; n=4, 10%), SOX (S-1 and 
oxaliplatin; n=1, 2%). We searched the medical records 
for variables, including preoperative laboratory results, 
preoperative MR images, surgical records, pathologic 
reports, the post-operative course, and the long-term 
follow-up course.
Imaging techniques
All patients underwent a pre-operative liver MRI. 
The mean time interval between preoperative gadoxetic 
acid-enhanced MRI and surgery was 35 days (range: 
1-171days). These studies were performed on 3.0 T MR 
scanners for 96 patients (Magnetom Trio Tim; Siemens 
Medical Solutions, Erlangen, Germany [n=66] or Achieva; 
Philips Medical Systems, Best, the Netherlands [n=30], 
with a body phased-array coil).
Contrast-enhanced dynamic MRI was performed 
after a rapid bolus injection of gadoxetic acid disodium 
(Primovist, Bayer Schering; 0.025 mmol/kg), followed 
by a saline flush of 15–20 ml with an injection rate of 
2 mL/sec. A three-dimensional (3D) T1-weighted spoiled 
GRE sequence with chemically selective fat suppression 
(2.54–3.03 ms/0.9–1.4 ms/13°/256×192/2 mm/0 mm) 
was performed at 25–30 seconds (arterial phase), 55–70 
seconds (portal phase), 100–180 seconds (transitional 
phase), and 15–20 minutes (hepatobiliary phase). T2-
weighted images were obtained by multi-shot and single-
shot turbo spin echo sequences using a navigator-triggered 
technique, with a section thickness, gap, repetition time, 
and echo time of 5–7 mm, 1 mm, 1589–3250 msec, and 
70–96 msec, respectively.
Image analysis
Qualitative analysis
The HBP phases of liver MR imaging were reviewed 
in consensus by a radiologist (J.Y.C.) with 16 years 
of experience in liver MRI and by a radiology resident 
(S.H.P.). These radiologists were blinded to all clinical and 
pathology data. We evaluated the SI of the largest CRLM 
relative to the background liver parenchyma. CRLMs 
were defined as clearly hypointense nodules if the signal 
intensity of the nodule showed a homogenous low signal 
intensity similar to that of the hepatic segment of inferior 
vena cava. A mixed hypointense nodule was defined as a 
lesion (at least partly) showing a signal intensity higher 
than that of the inferior vena cava.
Quantitative analysis
Quantitative parameters were calculated by drawing 
the region of interest (ROI) on the HBP image displayed by 
the PACS system (GE Medical Systems, Milwaukee, WI, 
USA). One investigator (S.H.P.) drew the maximum ROI 
at the largest diameter of the tumor and similar sized ROI 
in the adjacent homogenous liver parenchyma, avoiding 
vessels and the bile duct. Four parameters were calculated 
by the following equations. (1) The relative intensity 
ratio on the HBP image (RIRpost) = SI of the nodule on 
the HBP image/SI of the liver parenchyma on the HBP 
image. (2) The relative intensity ratio on the precontrast 
image (RIRpre) = SI of the nodule on the precontrast image/
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SI of the liver parenchyma on the precontrast image. (3) 
The relative enhancement ratio (RER) = RIRpost/RIRpre. (4) 
The contrast to noise ratio (CNR) = (SI of the nodule on 
the HBP image – SI of the liver parenchyma on the HBP 
image)/standard deviation (SD) of the liver parenchyma 
on the HBP image.
Histopathology analysis
Formalin-fixed, paraffin-embedded specimens 
from the nodules examined on MRI were selected for 
histopathologic analyses. Consecutive sections were 
obtained for H&E staining and immunohistochemistry. 
H&E stained specimens were reviewed by a pathologist 
(E.K.K.) for a tumor component analysis. The pathologist 
was aware that the specimens were colorectal cancer 
liver metastatic lesions as well as the location and size 
of the tumors to match the corresponding imaging but 
was blinded to all other clinical and MRI data. A semi-
quantitative 4-point scoring system was applied to 
measure fibrosis, necrosis, and cellularity by the following 
criteria: grade 1 (G1), the area of each component was 
<25% of the tumor area; grade 2 (G2), 25% to 50% of the 
tumor area; grade 3 (G3), 50% to 75% of the tumor area, 
and grade 4 (G4), >75% of the tumor area. In this study, 
grade 1 was defined as “low-grade” while grades 2-4 were 
defined as “high-grade”.
Immunohistochemistry was performed using 
a rabbit polyclonal anti-human OATP1B3 antibody 
(HPA004943; Sigma–Aldrich, St. Louis, MO, USA) 
as previously described [13]. Briefly, each section was 
deparaffinized, rehydrated, and antigen retrieved. The 
sectioned slides were incubated for 1 hour at room 
temperature with blocking solution containing 5% goad 
serum in PBST (0.3% Triton X-100 in phosphate buffered 
saline). After blocking, the sectioned samples were 
incubated overnight at 4°C with the primary antibody 
(rabbit polyclonal anti-human OATP1B3 antibody). 
After several washes in PBST, the slides were incubated 
with horseradish peroxidase-conjugated anti-rabbit 
IgG antibody. The immune reaction was visualized 
using 3,3’-diaminobenzidine (DAB). The slides were 
counter-stained with hematoxylin. The specificity of 
immunohistochemical staining was verified by omitting 
either the primary or secondary antibody.
The staining intensities were evaluated by a 
pathologist (E.K.K.) using the following categories: 
negative, weakly positive, moderately positive, and 
strongly positive (Supplementary Figure 4). The normal 
colonic mucosa shows negative OATP1B3 staining and 
therefore sections scored as weakly positive or higher 
were defined as OATP1B3-positive [13].
Statistical analysis
All statistical analyses were performed using 
IBM SPSS 20.0 software (IBM Corp., Armonk, NY, 
USA). A Chi-square test was performed to compare the 
enhancement pattern between the non-chemotherapy group 
and the chemotherapy group. A univariate binary logistic 
regression was performed to evaluate the relationship 
between the histopathologic components and the 
qualitative enhancement pattern. Thereafter a multivariate 
binary logistic regression was performed for all variables. 
By a similar method, univariate and multivariate linear 
logistic regressions were performed for the quantitative 
parameters. To compare disease-free survival and overall 
survival, a Kaplan-Meier survival analysis and a log-
rank test were used. Patients lost to follow-up or that 
died due to unrelated causes were regarded as censored 
data. A value of P<0.05 was considered to be statistically 
significant.
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